Canopy Growth Faces a Defining Moment as Medicare Pilot and Earnings Report Converge

US rescheduling of marijuana to Schedule III slashes tax burdens and unlocks Medicare coverage, boosting Canopy Growth's expansion prospects despite ongoing losses.

A sweeping shift in US drug policy is set to reshape the competitive landscape for cannabis companies, and Canopy Growth finds itself at the epicentre of the change. When Medicare began covering certain CBD and hemp products for the first time in April 2026, it opened a distribution channel that had been strictly off-limits for federally insured patients. For Canopy, which has long maintained a medical infrastructure in North America, the development unlocks access to millions of subsidised patients—a pool of demand that simply did not exist before.

The catalyst for this transformation is the reclassification of marijuana to Schedule III under US federal law. That change, now confirmed, allows physicians to more easily incorporate cannabis-based treatments into standard care. It also dismantles one of the industry’s most punishing financial burdens: Internal Revenue Code Section 280E, which previously barred cannabis companies from deducting ordinary business expenses. Under the old regime, effective tax rates were cripplingly high. With the rescheduling, Canopy’s tax rate is expected to fall in line with the standard corporate level of roughly 21%, freeing up significant cash that management can plough directly into its US expansion strategy.

The market has taken notice. By late April, Canopy’s stock was trading more than 31% above its 20-day moving average, and the longer-term trend had turned positive, with the share price sitting 11.3% above its 200-day line. The company’s market capitalisation stands at approximately $720 million, supported by third-quarter revenue of C$74.5 million and a cash position of C$371 million.

Yet the path to sustained profitability remains fraught. Over the past twelve months, Canopy has accumulated a loss of C$327 million. The adjusted operating loss narrowed to just C$3 million in the third quarter, but the company is still burning through capital as it restructures. A major recapitalisation in January extended all debt maturities to 2031 but diluted existing shareholders, and the subsequent acquisition of MTL Cannabis was financed largely with new equity. The number of outstanding shares has risen noticeably as a result.

Investors will get their first detailed look at how that deal is performing when Canopy reports its full-year results on 29 May 2026 (the company had previously flagged 30 May, but the date has been confirmed as the 29th). The MTL acquisition is expected to contribute roughly C$84 million in annual revenue, and management is betting on significantly higher gross margins to push the group toward a positive adjusted operating profit by fiscal 2027.

The stock has been volatile in the run-up. A brief surge in late April, when the US rescheduling news broke, sent shares up 28% to $1.51 before the rally evaporated. The price quickly fell back to $1.28 and has since settled around $1.18. The reason for the pullback is straightforward: the Medicare pilot applies only to federally licensed products, and a Canadian producer like Canopy does not benefit directly from US domestic policy changes. The real advantage comes indirectly, through its “Canopy USA” network, which uses exchangeable shares to access US brands such as Wana and Jetty, and through the tax relief that the Schedule III reclassification provides.

On the operational front, the company is also refreshing its leadership in Germany. David Männer took over as head of the vaporiser subsidiary Storz & Bickel in early April, succeeding co-founder Jürgen Bickel. Männer, a 14-year company veteran, is tasked with driving product innovation and expanding the brand’s presence in the US market.

The upcoming earnings release will be the first to include a full quarter of MTL’s contribution, and analysts will be watching closely for evidence that the margin improvements management has promised are materialising. Without measurable progress, the goal of reaching profitability by 2027 will remain a distant ambition. For now, Canopy Growth is balancing a historic policy tailwind against the hard realities of a balance sheet still in transition.